Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

Blighter's reputation enhanced by the success of its deployment of over one Blighter B400 series solid-state, non-rotating, low power and near zero maintenance electronic-scanning radar units along ...